|
AstraZeneca PLC on Monday announced its candidate for unresectable liver cancer Tremelimumab has been accepted under priority review by the US Food & Drug Administration.
Patients with unresectable liver cancer will receive the antibody in combination with AstraZeneca's immunotherapy Imfinzi, also known as Durvalumab, the Cambridge-based drugmaker said.
A phase III study with the two AstraZeneca products highlighted ‘the potential for this regimen to improve longer-term survival outcomes,’ explained Susan Galbraith, executive vice president of the oncology research & development arm of AstraZeneca.
AstraZeneca shares were 0.8% lower at 10,200.00 pence each in London on Monday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
